Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. META
4. MU
5. SPY
6. ACN
7. NVDA
8. IBM
9. PRIM
10. PFE

Go back to Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)
(NASDAQ: ROIV) Delayed: 31.46 +0.21 (0.67%)
Previous Close $31.25    52 Week High $ 
Open $31.05    52 Week Low $ 
Day High $31.74    P/E N/A 
Day Low $30.70    EPS $ 
Volume 1,969,972       

(NASDAQ: ROIV) Delayed: 31.46 +0.21 (0.67%)
Previous Close $31.25    52 Week High $ 
Open $31.05    52 Week Low $ 
Day High $31.74    P/E N/A 
Day Low $30.70    EPS $ 
Volume 1,969,972